Novo Nordisk heads into Monday facing a blunt question from investors: what's the growth plan after Wegovy? The Danish drugmaker, which rode a wave of demand for its blockbuster obesity treatment, is now under pressure to show it can thrive once the patents on semaglutide—the active ingredient in Wegovy and Ozempic—start expiring early next decade.
Analysts are pressing CEO Mike Doustdar for medium-term targets and a clearer path beyond obesity drugs. The concern is familiar to anyone who has watched the pharmaceutical industry: the so-called "patent cliff," when copycat versions of a drug hit the market and erode prices and market share.
The rise and the looming fall
Novo Nordisk launched Wegovy in 2021, and demand was explosive. The drug, along with Ozempic for diabetes, turned the company into a household name and briefly made it Europe's most valuable listed company in 2023. Investors piled in, betting that the obesity market would keep growing for years.
But the market has started looking past today's sales race. Rival Eli Lilly has been gaining ground with its own obesity treatments, and the clock is ticking on semaglutide's patent protection. When patents expire, generic versions could flood the market, much as they have for other blockbuster drugs in the past.
For context, patent expirations are a normal part of the drug industry's life cycle. Companies typically try to offset the loss with new products, line extensions, or by developing drugs for new indications. The question for Novo Nordisk is whether it has enough in the pipeline to fill the gap.
What investors want to hear
At the heart of the pressure is a demand for clarity. Analysts want to know what the company's growth will look like in the late 2020s and early 2030s, and how it plans to diversify beyond the obesity franchise that has driven its recent success.
That could mean more details on other pipeline candidates, partnerships, or acquisitions. It could also mean a more explicit strategy for defending its market position against Eli Lilly, which has been aggressive in pricing and development.
Investors are also likely to watch for any signs that Novo Nordisk is preparing for a smoother transition—for example, by developing next-generation obesity drugs that could replace Wegovy before the patent cliff hits.
What it means for investors
For everyday investors, the situation is a reminder that even the most successful companies face long-term challenges. A stock that has soared on the back of a single product can stumble when that product's growth slows or faces competition.
The key is to focus on the company's ability to adapt. Novo Nordisk has a strong track record in diabetes and obesity, but the market is becoming more crowded. Eli Lilly's progress is a direct threat, and the patent expirations are a fixed date on the calendar.
Investors should also consider the broader context. The obesity drug market is still young, and demand is expected to remain strong for years. But the competitive landscape is shifting, and companies that fail to innovate could see their margins squeezed.
As Novo Nordisk prepares to address investors, the message will be about more than just the next quarter. It will be about the next decade. And for shareholders, the stakes are high.
For more on how global markets are reacting to similar pressures, see our coverage of which global markets look cheap or pricey and the latest on Japan's bond yields as investors await central bank cues.
